Greenland Approves CRML's Tanbreez Stake; Execution Risks Persist

What happened

Critical Metals Corp. received formal Greenland government approval for its previously announced acquisition of a 70% interest in 60° North ApS, which holds the Tanbreez heavy rare-earth project. While this removes a key regulatory hurdle, the DeepValue report rates CRML a STRONG SELL, citing its pre-revenue status, going-concern uncertainty, and dependence on securing non-dilutive project financing. The company still needs to convert a stack of non-binding offtake LOIs and a Saudi JV term sheet into definitive agreements, complete a Bankable Feasibility Study, and obtain final exploitation approvals before end-2028. With only $7.3 million in cash and persistent operating losses, CRML remains reliant on equity or debt raises to fund development, and the stock's $1.23 billion market cap prices in a smooth execution sequence that is far from assured. The Greenland approval is a necessary but insufficient step; the core investment thesis remains highly speculative.

Implication

For investors, the Greenland approval removes one political risk factor but does little to alter the company's fundamental challenge: funding two capital-intensive, pre-revenue projects. CRML still needs to convert the EXIM Bank LOI into a binding loan, finalize the Saudi JV on carried terms, and secure binding offtakes—all while managing a thin balance sheet. The stock's rally on this news may present a selling opportunity for holders, as the risk-reward skew remains unfavorable. New investors should wait for tangible de-risking events, such as definitive EXIM documentation or a binding offtake, before considering entry. We maintain our Strong Sell rating and $6–11 fair value range, as the Greenland approval was already anticipated and priced into the stock's elevated multiple.

Thesis delta

The Greenland approval partially de-risks the Tanbreez regulatory path, but does not address the more critical financing and commercial conversion risks that underpin our strong sell thesis. The probability of a smooth execution sequence remains low, and the stock's current valuation does not adequately discount the high likelihood of dilution or project delays. Our base case valuation of $11 remains unchanged, and we see no reason to adjust our rating or fair value range based on this news.